ZES
MCID: ZLL002
MIFTS: 53

Zollinger-Ellison Syndrome (ZES)

Categories: Endocrine diseases, Gastrointestinal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Zollinger-Ellison Syndrome

MalaCards integrated aliases for Zollinger-Ellison Syndrome:

Name: Zollinger-Ellison Syndrome 11 19 58 75 53 43 14 16 71 33
Gastrinoma 19 58 71
Pancreatic Ulcerogenic Tumor Syndrome 19
Ze - [zollinger-Ellison] Syndrome 33
Z E Syndrome 19
Zes 19

Characteristics:


Prevelance:

1-9/1000000 (Europe, Denmark, Worldwide) 1-9/100000 (Europe) <1/1000000 (Ireland) 58

Age Of Onset:

Adult,Elderly 58

Classifications:

Orphanet: 58  
Rare gastroenterological diseases
Rare endocrine diseases


Summaries for Zollinger-Ellison Syndrome

GARD: 19 Zollinger-Ellison syndrome (ZES) is a condition in which tumors called gastrinomas in the pancreas and duodenum (part of the small intestine) cause high levels of the hormone gastrin in the blood. High levels of gastrin then cause production of too much stomach acid. Signs and symptoms may include abdominal pain, peptic ulcers, vomiting blood, and diarrhea. The tumors are sometimes cancerous and may spread to other areas of the body. In most cases, the cause of ZES is unknown. However, about 25-30% of gastrinomas are caused by an inherited condition called multiple endocrine neoplasia type 1 (MEN1).

MalaCards based summary: Zollinger-Ellison Syndrome, also known as gastrinoma, is related to gastrinoma and multiple endocrine neoplasia, and has symptoms including dyspepsia An important gene associated with Zollinger-Ellison Syndrome is GAST (Gastrin), and among its related pathways/superpathways are Class A/1 (Rhodopsin-like receptors) and GPCR downstream signalling. The drugs Dexlansoprazole and Lansoprazole have been mentioned in the context of this disorder. Affiliated tissues include pancreas, small intestine and pituitary, and related phenotypes are zollinger-ellison syndrome and peptic ulcer

Disease Ontology: 11 A syndrome that is characterized by the development of a one or more tumors (gastrinoma) in the pancreas, duodenum, or both that secrete excessive levels of gastrin, a hormone that stimulates production of acid by the stomach.

Orphanet: 58 Zollinger-Ellison syndrome (ZES) is characterized by severe peptic disease (ulcers/esophageal disease) caused by hypergastrinemia secondary to a gastrinoma resulting in increased gastric acid secretion.

Wikipedia: 75 Zollinger-Ellison syndrome (Z-E syndrome) is a disease in which tumors cause the stomach to produce too... more...

Related Diseases for Zollinger-Ellison Syndrome

Diseases related to Zollinger-Ellison Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 403)
# Related Disease Score Top Affiliating Genes
1 gastrinoma 32.0 SST SCT MEN1 GRP GAST CHGA
2 multiple endocrine neoplasia 31.6 SST SCT MEN1 GAST CHGA
3 islet cell tumor 31.5 SST SCT MEN1 GHRH GAST CHGA
4 carcinoid tumors, intestinal 31.5 SST MEN1 GAST CHGA
5 hyperparathyroidism 31.4 SCT MEN1 GAST CHGA
6 esophagitis 31.2 NTS MLN HRH2 GAST
7 primary hyperparathyroidism 31.1 SCT MEN1 GAST CHGA
8 pancreatic endocrine carcinoma 31.1 SST MEN1 GAST CHGA
9 parathyroid adenoma 31.1 MEN1 GAST CHGA
10 gastric neuroendocrine neoplasm 30.9 SST MEN1 GAST CHGA ATP4A ATP12A
11 diarrhea 30.9 SST SCT NTS MLN HRH2 GAST
12 carcinoid syndrome 30.9 SST NTS GHRH CHGA
13 adenoma 30.9 SST MEN1 GHRH CHGA
14 insulinoma 30.9 SST SCT MEN1 GAST CHGA
15 duodenal ulcer 30.7 SST SCT MLN HRH2 GRP GAST
16 pituitary tumors 30.7 SST MEN1
17 multiple endocrine neoplasia, type i 30.7 SST SCT MEN1 GHRH GAST CHGA
18 conn's syndrome 30.7 SST MEN1 GHRH CHGA
19 acromegaly 30.5 SST MEN1 GHRH
20 hyperinsulinemic hypoglycemia 30.5 SST SCT MEN1 GAST CHGA
21 neuroendocrine tumor 30.5 SST SCT NTS MEN1 GRP GAST
22 gastric ulcer 30.5 SST HRH2 GAST EGF ATP12A
23 pituitary adenoma 30.5 SST MEN1 GHRH CHGA
24 glucagonoma 30.5 SST SCT GAST CHGA
25 hypoglycemia 30.4 SST SCT GHRH GAST CHGA
26 peptic ulcer disease 30.4 SST SCT MEN1 HRH2 GAST ATP4A
27 barrett esophagus 30.4 GAST ATP4A ATP12A
28 gastritis 30.4 SST SCT HRH2 GAST CHGA ATP4A
29 prolactinoma 30.3 SST MEN1 EGF CHGA
30 pyloric stenosis 30.3 SST MLN GAST
31 ectopic cushing syndrome 30.3 SST CHGA
32 secretory diarrhea 30.3 SST GAST
33 pituitary gland disease 30.3 SST MEN1 GHRH
34 irritable bowel syndrome 30.3 SST MLN CHGA
35 hyperinsulinemic hypoglycemia, familial, 2 30.2 SST SCT GAST CHGA
36 gastrojejunal ulcer 30.2 ATP4A ATP12A
37 pernicious anemia 30.2 SST GAST CHGA ATP4A ATP12A
38 small cell cancer of the lung 30.2 SST GRP GAST CHGA
39 neuroendocrine carcinoma 30.2 SST MEN1 GRP GAST CHGA
40 peptic esophagitis 30.1 MLN HRH2 GAST ATP4A ATP12A
41 somatostatinoma 30.1 SST MEN1 GHRH GAST CHGA
42 functioning pituitary adenoma 30.1 SST MEN1 GHRH
43 short bowel syndrome 30.0 SST NTS GAST EGF
44 celiac disease 1 30.0 SCT GAST ATP4A ATP12A
45 duodenum cancer 30.0 SST SCT MEN1 GAST CHGA
46 dumping syndrome 29.9 SST SCT NTS MLN GAST
47 gastrointestinal stromal tumor 29.8 SST MEN1 EGF CHGA
48 duodenitis 29.8 SST GAST ATP4A ATP12A
49 vitamin b12 deficiency 29.8 GAST ATP4A ATP12A
50 pancreatic cancer 29.8 SST SCT NTS MEN1 GRP GHRH

Graphical network of the top 20 diseases related to Zollinger-Ellison Syndrome:



Diseases related to Zollinger-Ellison Syndrome

Symptoms & Phenotypes for Zollinger-Ellison Syndrome

Human phenotypes related to Zollinger-Ellison Syndrome:

58 30 (show all 36)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 zollinger-ellison syndrome 58 30 Obligate (100%) Obligate (100%)
HP:0002044
2 peptic ulcer 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0004398
3 esophagitis 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0100633
4 duodenal ulcer 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002588
5 nausea 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002018
6 episodic abdominal pain 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002574
7 weight loss 58 30 Frequent (33%) Frequent (79-30%)
HP:0001824
8 jaundice 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000952
9 multiple lipomas 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001012
10 hyperparathyroidism 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000843
11 hypercalcemia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003072
12 erythema 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0010783
13 hematochezia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002573
14 intestinal obstruction 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0005214
15 lipoma 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012032
16 pituitary growth hormone cell adenoma 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0011760
17 pituitary prolactin cell adenoma 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0006767
18 adrenocortical adenoma 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0008256
19 extrahepatic cholestasis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012334
20 increased urinary cortisol level 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012030
21 pituitary corticotropic cell adenoma 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0008291
22 thyroid adenoma 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000854
23 elevated circulating parathyroid hormone level 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003165
24 pituitary null cell adenoma 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0011761
25 parathyroid hyperplasia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0008208
26 glucagonoma 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0030404
27 increased glucagon level 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0030688
28 increased circulating cortisol level 30 Occasional (7.5%) HP:0003118
29 elevated circulating growth hormone concentration 30 Occasional (7.5%) HP:0000845
30 adrenocortical carcinoma 58 30 Very rare (1%) Very rare (<4-1%)
HP:0006744
31 gastrointestinal hemorrhage 58 Occasional (29-5%)
32 growth hormone excess 58 Occasional (29-5%)
33 diarrhea 58 Very frequent (99-80%)
34 hypercortisolism 58 Occasional (29-5%)
35 neuroendocrine neoplasm 58 Obligate (100%)
36 pituitary adenoma 58 Occasional (29-5%)

UMLS symptoms related to Zollinger-Ellison Syndrome:


dyspepsia

GenomeRNAi Phenotypes related to Zollinger-Ellison Syndrome according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00249-S 9.4 HRH2 MLN
2 Decreased viability GR00381-A-1 9.4 GRP HRH2 MLN
3 Decreased viability GR00381-A-3 9.4 GRP HRH2 MLN
4 Decreased viability GR00386-A-1 9.4 GRP MLN
5 Decreased viability GR00402-S-2 9.4 GRP MLN

MGI Mouse Phenotypes related to Zollinger-Ellison Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.17 ATP12A ATP4A EGF GAST HRH2 MEN1

Drugs & Therapeutics for Zollinger-Ellison Syndrome

Drugs for Zollinger-Ellison Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 66)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6 9578005
2
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
3 Anti-Ulcer Agents Phase 4
4 Antacids Phase 4
5 Proton Pump Inhibitors Phase 4
6 Gastrointestinal Agents Phase 4
7
Esomeprazole Approved, Investigational, Vet_approved Phase 3 73590-58-6, 119141-88-7 9568614 4594
8
Fluorouracil Approved Phase 2 51-21-8 3385
9
Pancrelipase Approved, Investigational Phase 2 53608-75-6 8519
10
Streptozocin Approved, Investigational Phase 2 18883-66-4, 66395-18-4 29327
11
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
12
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
13
Pantoprazole Approved Phase 2 102625-70-7, 138786-67-1 4679
14
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
15
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
16
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
17
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
18
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
19
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
20
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
21
Somatostatin Approved, Investigational Phase 2 38916-34-6, 51110-01-1 53481605 16129706
22
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
23
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
24
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
25 Pancreatin Phase 2
26 Liposomal doxorubicin Phase 2
27 Antiviral Agents Phase 2
28 Anti-Infective Agents Phase 2
29 interferons Phase 2
30 Protein Kinase Inhibitors Phase 2
31 Angiogenesis Inhibitors Phase 2
32 Antineoplastic Agents, Immunological Phase 2
33 Immunoglobulins, Intravenous Phase 2
34 Immunoglobulins Phase 2
35 Immunoglobulin G Phase 2
36 Antifungal Agents Phase 2
37 Antibodies, Monoclonal Phase 2
38 Antibodies Phase 2
39 Endothelial Growth Factors Phase 2
40 Mitogens Phase 2
41 Antineoplastic Agents, Hormonal Phase 2
42 Antimetabolites Phase 2
43 Alkylating Agents Phase 2
44 Antineoplastic Agents, Alkylating Phase 2
45 Radiopharmaceuticals Phase 2
46 Edotreotide lutetium LU-177 Phase 2
47
Edotreotide Phase 2 23724894
48 Anti-Bacterial Agents Phase 2
49 Antibiotics, Antitubercular Phase 2
50 Immunosuppressive Agents Phase 2

Interventional clinical trials:

(show all 30)
# Name Status NCT ID Phase Drugs
1 Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors Completed NCT00204373 Phase 4 Lansoprazole (Prevacid)
2 A Phase III, Multicenter, Open-Label Study To Evaluate the Control of Gastric Acid Secretion With Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome For 12 Months Completed NCT00079833 Phase 3 Esomeprazole magnesium (Nexium)
3 An Open-label, Parallel-group, Multi-centre, Phase I/III Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Repeated Once-daily Oral Administration of D961H 10 mg and D961H 20 mg in Japanese Paediatric Patients 1 to 14 Years Old With Gastrointestinal Acid Related Diseases Completed NCT02153398 Phase 3 D961H sachet 10 mg;D961H capsule 10mg;D961H capsule 20 mg
4 Evaluation of Chemotherapy With Streptozotocin Combined With 5-Fluorouracil and Adriamycin in Patients With Zollinger-Ellison Syndrome and Metastatic Non-Beta-Islet Cell Neoplasm Completed NCT00001165 Phase 2 combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
5 Evaluation of Treatment With Interferon, Octreotide, or Their Combination in Patients With Zollinger-Ellison Syndrome and Progressive Metastatic Non-B Islet Cell Neoplasm Completed NCT00001228 Phase 2 Interferon
6 The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid Completed NCT00001191 Phase 2 Pantoprazole;Omeprazole
7 Phase II Study of Single Agent Regorafenib in Patients With Advanced/Metastatic Neuroendocrine Tumors Completed NCT02259725 Phase 2 regorafenib
8 A Phase II Trial of ZD1839 (Iressa®) in Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
9 A Phase II Trial of Bay 43-9006 in Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
10 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
11 Randomized Phase II Study of Everolimus Alone Versus Everolimus Plus Bevacizumab in Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors Completed NCT01229943 Phase 2 Everolimus;Octreotide Acetate
12 A Phase 2 Study of Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Completed NCT01525082 Phase 2 Capecitabine;Temozolomide
13 A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
14 A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01824875 Phase 2 temozolomide;capecitabine
15 A Prospective Randomized Study of the Efficacy and Safety of 177Lu-DOTATOC With Either Standard or Personalized Dosing for the Treatment of Patients With Somatostatin Receptor Positive NETs Not yet recruiting NCT04915144 Phase 2 177Lu-DOTATOC
16 A Pilot Trial of YF476, a Gastrin Antagonist, in Patients With Type II Gastric Carcinoids Associated With Zollinger-Ellison Syndrome Terminated NCT02454075 Phase 2 YF476
17 A Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the Liver Terminated NCT02031536 Phase 2 everolimus
18 Phase II Evaluation of Real-Time, Pharmacokinetically Guided Everolimus in Patients With Hormone Receptor Positive Breast Cancer, Pancreatic Neuroendocrine Tumors (PNET), and Renal Cell Carcinoma Terminated NCT02273752 Phase 2 Everolimus
19 Phase II Study of Depsipeptide in Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
20 Phase II Study of Dovitinib (TKI-258) in Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors With and Without Prior VEGF-Inhibitor Therapy Withdrawn NCT02108782 Phase 2 dovitinib lactate
21 A Phase I Trial of the mTOR Inhibitor RAD001 in Combination With VEGF Receptor Tyrosine Kinase Inhibitor PTK787/ZK 222584 in Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
22 Phase I Feasibility Trial To Study The Safety Of Sealing Resected Pancreatic Surfaces After Partial Distal Pancreatectomy Using Laser Tissue Welding Completed NCT03147768 Phase 1
23 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
24 Phase I Study of Anti-IGF-1R Monoclonal Antibody, IMC-A12, and mTOR Inhibitor, Everolimus, in Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
25 A Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
26 Medical Therapy of Zollinger-Ellison Syndrome Completed NCT00001241
27 Evaluation of the Gastrinoma in Patients With Zollinger-Ellison Syndrome Completed NCT00001254
28 Diagnostic Evaluation of Patients With Suspected Abnormalities of Gastric Secretion Completed NCT00001240
29 Nexium Capsules Clinical Experience Investigation Completed NCT01434485
30 Evaluation of the Safety and Sensitivity of 68Ga-DOTATOC PET/CT for Imaging NET Patients Recruiting NCT03583528

Search NIH Clinical Center for Zollinger-Ellison Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cimetidine
Cimetidine Hydrochloride
Famotidine
lansoprazole
Nizatidine
Omeprazole
Omeprazole 2 MG/ML Oral Suspension
Omeprazole magnesium
pantoprazole
Pantoprazole sodium
rabeprazole

Cochrane evidence based reviews: zollinger-ellison syndrome

Genetic Tests for Zollinger-Ellison Syndrome

Anatomical Context for Zollinger-Ellison Syndrome

Organs/tissues related to Zollinger-Ellison Syndrome:

MalaCards : Pancreas, Small Intestine, Pituitary, Liver, Thyroid, Lymph Node, Pancreatic Islet

Publications for Zollinger-Ellison Syndrome

Articles related to Zollinger-Ellison Syndrome:

(show top 50) (show all 2996)
# Title Authors PMID Year
1
[Zollinger-Ellison syndrome: a case report.]. 53 62
20423792 2010
2
Diagnostic efficacy of the secretin stimulation test for the Zollinger-Ellison syndrome: an intra-individual comparison using different dosages in patients and controls. 53 62
20299818 2010
3
False-positive secretin stimulation test for gastrinoma associated with the use of proton pump inhibitor therapy. 53 62
19245850 2009
4
Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case report. 53 62
18376130 2008
5
Secretin-receptor and secretin-receptor-variant expression in gastrinomas: correlation with clinical and tumoral features and secretin and calcium provocative test results. 53 62
17711922 2007
6
Chromogranin A: is it a useful marker of neuroendocrine tumors? 53 62
17513802 2007
7
Diagnosis and differential diagnosis of hypergastrinemia. 53 62
17985088 2007
8
Gastrinoma--morphological aspects. 53 62
17985091 2007
9
Review article: Pathogenesis and management of gastric carcinoid tumours. 53 62
17059512 2006
10
Increased islet beta cell replication adjacent to intrapancreatic gastrinomas in humans. 53 62
17016695 2006
11
Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. 53 62
17006979 2006
12
[Pseudo Zollinger-Ellison syndrome in a patient with duodenal stenosis caused by tuberculosis]. 53 62
16505764 2005
13
Double doses of secretin contribute to diagnosis of Zollinger-Ellison syndrome in secretin and selective arterial secretion injection tests--a case report. 53 62
16240211 2005
14
Precursor lesions in patients with multiple endocrine neoplasia type 1-associated duodenal gastrinomas. 53 62
15887103 2005
15
Intravenous calcium injection test is a novel complementary procedure in differential diagnosis for gastrinoma. 53 62
12205549 2002
16
The serological gastric biopsy: a non-endoscopical diagnostic approach in management of the dyspeptic patient: significance for primary care based on a survey of the literature. 53 62
12408500 2002
17
Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. 53 62
11701693 2001
18
A randomized controlled crossover study comparing synthetic porcine and human secretins with biologically derived porcine secretin to diagnose Zollinger-Ellison Syndrome. 53 62
11328261 2001
19
Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. 53 62
11136282 2001
20
Curative resection of microgastrinomas based on the intraoperative secretin test. 53 62
11038217 2000
21
Bleeding from alimentary tract in pseudo Zollinger-Ellison syndrome. 53 62
11208377 2000
22
Ovarian mucinous cystadenocarcinoma as a cause of Zollinger-Ellison syndrome: report of a case and review of the literature. 53 62
10811352 2000
23
Histomorphological characteristics of gastric mucosa in patients with Zollinger-Ellison syndrome or autoimmune gastric atrophy: role of gastrin and atrophying gastritis. 53 62
10738314 2000
24
Fundic gland polyps: a still elusive entity on the eve of the year 2000. 53 62
10833897 2000
25
The effect of Zollinger-Ellison syndrome and neuropeptide-secreting tumors on the stomach. 53 62
10980995 1999
26
Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas. 53 62
10193936 1999
27
Pancreatic endocrine tumors: recent advances. 53 62
10436815 1999
28
[The coexistence of 2 different neuroendocrine tumors of the upper gastrointestinal tract and pancreas]. 53 62
9861888 1998
29
Relationship between fundic endocrine cells and gastric acid secretion in hypersecretory duodenal ulcer diseases. 53 62
9726392 1998
30
Hypergastrinemia and enterochromaffin-like cell hyperplasia. 53 62
10461360 1998
31
[Gastric neuroendocrine tumor]. 53 62
10068736 1998
32
Management of patients and subjects at risk for multiple endocrine neoplasia type 1: MEN 1. GENEM 1. Groupe d'Etude des Néoplasies Endocriniennes Multiples de type 1. 53 62
9167954 1997
33
Use of calcium provocative test in the diagnosis of gastroenteropancreatic endocrine tumors. 53 62
9063035 1996
34
Adenocarcinoid of the liver arising within an area of hamartoma with predominant bile duct component. 53 62
8877646 1996
35
Prolonged hypergastrinemia does not increase the frequency of colonic neoplasia in patients with Zollinger-Ellison syndrome. 53 62
8617144 1996
36
Serum gastrin and secretin test in Zollinger-Ellison syndrome. 53 62
8551921 1996
37
Metastatic gastrinomas: localization with selective arterial injection of secretin. 53 62
8539410 1996
38
Endocrine tumors of the small and large intestine. 53 62
7479353 1995
39
Accuracy and precision of serum gastrin measurements in commercial laboratories. 53 62
8520176 1995
40
Gastrinomas demonstrate amplification of the HER-2/neu proto-oncogene. 53 62
7911296 1994
41
Treatment of peptic ulcers from now to the millennium. 53 62
7949462 1994
42
Laboratory medicine in ulcer disease. 53 62
7923753 1994
43
[Somatostatin receptor scintigraphy in neuroendocrine tumors exemplified by a patient with hepatic metastases of gastrinoma]. 53 62
7513113 1994
44
The pathology of the gastrointestinal endocrine system. 53 62
8125073 1993
45
Parenteral control of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. 53 62
8104773 1993
46
Management of patients with the Zollinger-Ellison syndrome. 53 62
7901311 1993
47
Use of selective arterial secretin injection test to guide surgery in patients with Zollinger-Ellison syndrome. 53 62
8362526 1993
48
Ovarian cancers express and process progastrin. 53 62
8467501 1993
49
Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients. 53 62
8323758 1993
50
[Zollinger-Ellison syndrome with basal gastrin and non-diagnostic stimulation tests (secretin and calcium)]. 53 62
8429704 1993

Variations for Zollinger-Ellison Syndrome

Expression for Zollinger-Ellison Syndrome

Search GEO for disease gene expression data for Zollinger-Ellison Syndrome.

Pathways for Zollinger-Ellison Syndrome

GO Terms for Zollinger-Ellison Syndrome

Cellular components related to Zollinger-Ellison Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.06 SST SCT GRP GHRH GAST EGF
2 extracellular region GO:0005576 9.91 SST SCT NTS MLN GRP GHRH
3 neuronal dense core vesicle GO:0098992 8.92 SST GRP CHGA

Biological processes related to Zollinger-Ellison Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sodium ion export across plasma membrane GO:0036376 9.56 ATP4A ATP12A
2 cellular potassium ion homeostasis GO:0030007 9.46 ATP4A ATP12A
3 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.26 ATP4A ATP12A
4 positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway GO:1900738 8.92 GRP CHGA

Molecular functions related to Zollinger-Ellison Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 P-type sodium:potassium-exchanging transporter activity GO:0005391 9.62 ATP4A ATP12A
2 P-type potassium:proton transporter activity GO:0008900 9.46 ATP4A ATP12A
3 neuropeptide hormone activity GO:0005184 9.43 NTS GRP GHRH
4 hormone activity GO:0005179 9.28 SST SCT MLN GHRH GAST
5 P-type potassium transmembrane transporter activity GO:0008556 9.26 ATP4A ATP12A

Sources for Zollinger-Ellison Syndrome

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....